title: Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
abstract: The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% of patients had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), and surgery/trauma (15%) were the predominant underlying conditions. A successful therapeutic response was achieved in 57% of patients (median, 103 therapy days), with > 98% of those responding receiving > or = 28 days of therapy. Patients receiving primary therapy showed a 61% response versus 56% for the others. The best therapeutic responses were seen for skin/subcutaneous (91%) or bone (79%) infections, and the lowest for CNS infections (43%). Patients without major immune suppression (72%) or those with solid organ transplantation (63%) or various hematological conditions (60%) showed the best responses by underlying condition. Median known survival time was 133 days (therapy successes, 252 days; failures, 21 days). In all, 43 (40%) patients died, 73% due to scedosporiosis. Patients with Scedosporium prolificans infection had significantly reduced survival times (P = 0.0259) and were more likely to die from fungal infection (P = 0.002) than were Scedosporium apiospermum-infected patients. In a subset of 43 patients where voriconazole baseline MICs were available, response to voriconazole was higher for S. apiospermum-infected patients (54% response; MIC(50), 0.25 microg/ml) than for S. prolificans-infected patients (40% response; MIC(50), 4.0 microg/ml). Voriconazole demonstrated clinically useful activity in the treatment of both S. apiospermum and S. prolificans infections and was well tolerated.
authors.affiliation: The Old Court, Broadstairs, Kent CT10 3LW, United Kingdom. peter2troke@btinternet.com
authors.forename: Peter
authors.initials: P
authors.lastname: Troke
authors.forename: Koldo
authors.initials: K
authors.lastname: Aguirrebengoa
authors.forename: Carmen
authors.initials: C
authors.lastname: Arteaga
authors.forename: David
authors.initials: D
authors.lastname: Ellis
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Heath
authors.forename: Irja
authors.initials: I
authors.lastname: Lutsar
authors.forename: Montserrat
authors.initials: M
authors.lastname: Rovira
authors.forename: Quoc
authors.initials: Q
authors.lastname: Nguyen
authors.forename: Monica
authors.initials: M
authors.lastname: Slavin
authors.forename: Sharon C A
authors.initials: SC
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D005260:Female; D006306:Health Surveys; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D021681:Scedosporium / Q000187:drug effects*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole